EGFR 20 外显子插入（EGFR ex20ins）突变是非小细胞肺癌（NSCLC）中除 EGFR 19 外显子缺失（19-Del）和 21 外显子 L858R 点突变（21-L858R）两大常见突变外的 EGFR 第三大突变，占所有 NSCLC ...

Thus, Thermo Fisher researchers are confident that the anti-EGFR antibody is target-specific. In the cell nucleus, DNA is tightly packaged — wrapped around histone proteins to form chromatin.

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared ...

Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

KFDA approves Takedas Prucalopride capsules for metastatic colorectal cancer Approval granted for Takedas Prucalopride ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF genes (RAS/BRAF wild-type) are typically treated with EGFR inhibitors.

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

Purple Biotech’s growing intellectual property portfolio for NT219 in combination with anti-cancer standard-of-care therapies includes a previously issued U.S. patent that covers the pharmaceutical ...

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC ...